NDA 019882 · Curium
Technescan Mag3
Technetium Tc-99m Mertiatide Kit · Injection
NovelLast checked: Nov 19, 2026Latest source record: Jul 28, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1990
Jun 15, 1990
Approved uses
2
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
103
42 serious, 5 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 6, 2026.
INDICATIONS AND USAGE Technetium Tc 99m mertiatide is a renal imaging agent for use in the diagnosis of congenital and acquired abnormalities, renal failure, urinary tract obstruction, and calculi in adults and pediatric patients. (See Pediatric Use. ) It is a diagnostic aid in providing renal function, split function, renal angiograms, and renogram curves for whole kidney and renal cortex.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 27, 1992 Supplement 1 · Efficacy
- Jun 15, 1990 Original approval · Type 1 - New Molecular Entity
1 products under this application
- TECHNESCAN MAG3 · TECHNETIUM TC-99M MERTIATIDE KIT N/A · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Mertiatide Kit" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective16
- dyspnoea11
- radioisotope scan abnormal9
- renal scan abnormal8
- syncope8
- tachycardia7
- drug dispensing error6
- nausea6
- rash6
- vomiting6
- urticaria5
- wrong drug administered5
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 4 |
| 2009 | 4 |
| 2010 | 10 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 4 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 7 |
| 2018 | 10 |
| 2019 | 19 |
| 2020 | 22 |
| 2021 | 8 |
| 2022 | 1 |
| 2025 | 3 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Curium
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.